See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Dupixent Sales Spur Sanofi Growth, but Profits Fall Short - Pharmaceutical Technology

Summary by Pharmaceutical-technology.com
Heavy investment into R&D for Dupixent’s successor meant earnings per share fell short of expectations.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

pharmaceutical-technology.compharmaceutical-technology.com

Dupixent sales spur Sanofi growth, but profits fall short - Pharmaceutical Technology

Heavy investment into R&D for Dupixent’s successor meant earnings per share fell short of expectations.

Read Full Article
L'AGEFIL'AGEFI

Sanofi Disappoints with a Net Profit Below Expectations, Despite a Raised Sales Target

The laboratory anticipates an increase of about 9% in its annual turnover and more than 10% in its net profit per share.

Read Full Article
endpoints.newsendpoints.news

Sanofi rides Dupixent sales wave but profits fall short

Sanofi has inched up its full-year guidance on the back of another quarter of strong sales for its Regeneron-partnered drug Dupixent, which the French drugmaker said was catapulted by its recent ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Thursday, July 31, 2025.
Sources are mostly out of (0)

Similar News Topics

France icon

France

News
For You
SearchBlindspotLocal